Accolade (ACCD) closed the last trading session at $11.88, gaining 5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.07 indicates a 26.9% upside potential.The average comprises 14 short-term price targets ranging from a low of $12 to a high of $19, with a standard deviation of $2.06. While the lowest estimate indicates an increase of 1% from the current price level, the most o ...

One stock that might be an intriguing choice for investors right now is Accolade, Inc. (ACCD) . This is because this security in the Technology Services space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Technolo ...

andreswd Overview My recommendation for Accolade (NASDAQ:ACCD) is a buy rating, as I remain convicted that ACCD can grow 20% in FY25, driven by a strong core demand, health care plan strategy, GLP-1, and elevated demand for expert medical opinion. Note that I previously rated buy rating for ACCD as I expected ACCD to continue executing as guided and growing the business as I expected. As ACCD executes, valuation should re-rate to historical levels. Indeed, I believe the market recognized that valuation was ...

Accolade, Inc. (NASDAQ:ACCD) Q3 2024 Earnings Call Transcript January 8, 2024 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Conference Call Participants Ryan Daniels - Blair Craig Hettenbach - Morgan Stanley Ryan MacDonald - Needham Jailendra Singh - Truist Stan Berenshteyn - Wells Fargo Jessica Tassan - Piper Sandler Richard Close - Canaccord Genuity Allen Lutz - Bank of America Stephanie Davis - Barclays Jenny Shen - BTIG Jack Wallace - Guggenheim Partners O ...

January 2024 NASDAQ: ACCD ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ FORM 10-Q ______________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39348 ACCOLADE, INC. (Exa ...

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will be presenting at the following upcoming investor conferences: 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11 at 7:30am PT26th Annual Needham Growth Conference in New York on Thursday, January 18 at 3:00pm ET A webcast of these events will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (NASDAQ:ACCD) is a Persona ...

Accolade, Inc. (NASDAQ:ACCD) Q2 2024 Earnings Conference Call October 4, 2023 4:30 PM ET Company Participants Todd Friedman - Senior Vice President, Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Executive Vice President, Care Delivery and Chief Health Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Jessica Tassan - Piper Sandler Jailendra Singh - Truist Securities Jared Haase - William Blair Glen Santangelo - Jefferie ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39348 ACCOLADE, INC. (Exact name of registrant as specified in its charter) Delaware 01-0969591 (State or Other Juri sdiction of (I.R.S. ...

Accolade, Inc. (NASDAQ:ACCD) Q1 2024 Earnings Conference Call June 29, 2023 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Health Officer Conference Call Participants Ryan Daniels - Blair Craig Hettenbach - Morgan Stanley Jeff Garrow - Stephens, Inc. Jessica Tassan - Piper Sandler Stephanie Davis - SVB Securities Ryan MacDonald - Needham and Company Jonathan Yong - Credit Suisse Jailendra Singh - Truist Securities Sandy Draper - Guggenhei ...